For research use only. Not for therapeutic Use.
Alirocumab (REGN 727) is a human monoclonal antibody inhibitor of PCSK9. Alirocumab is a monoclonal antibody. Alirocumab has anti-inflammatory, antiangiogenic and antioxidant effects. Alirocumab can be used in the study of hypercholesterolemia[1][2][3][4][5].
Alirocumab (0.01, 0.1, 1, 2 and 10 μM, 24-72 h) does not affect cell viability and function in hiPSC-CMs and hESC-CMs, and can be used to evaluate drug safety in lipid-lowering cardiovascular cells[3].
Alirocumab (3 or 10 mg/kg, subcutaneous injection weekly for 18 weeks) inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin[4].
Alirocumab (10 mg/kg, intraperitoneal injection at day 0, 10, 20) inhibits PCSK9 in rats and improves systemic oxidative stress and hyperlipidemia in BDL-induced cirrhosis rats[5].
| Catalog Number | M144241 |
| CAS Number | 1245916-14-6 |
| Purity | ≥95% |
| Reference | [1]. Markham A. Alirocumab: First Global Approval. Drugs. 2015;75(14):1699-1705. [2]. Tavori H, et al. Alirocumab: PCSK9 inhibitor for LDL cholesterol reduction. Expert Rev Cardiovasc Ther. 2014 Oct;12(10):1137-44. [3]. Ni X, et al. Establishment of an in vitro safety assessment model for lipid-lowering drugs using same-origin human pluripotent stem cell-derived cardiomyocytes and endothelial cells. Acta Pharmacol Sin. 2022 Jan;43(1):240-250. [4]. Kühnast S, et al. Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin. J Lipid Res. 2014 Oct;55(10):2103-12. [5]. Huang HC, et al. Effects of PCSK-9 Inhibition by Alirocumab Treatments on Biliary Cirrhotic Rats. Int J Mol Sci. 2022 Jul 2;23(13):7378. |
